Patent has been approved in China

ProstaLund AB has received the positive news that a utility model application for their product CoreFlow Soft Stent has been approved in China.

A utility model patent is a form of simpler patent that can be maintained for 10 years, in this case until 2033.

CoreFlow® Soft Stent is a multifunctional product that can replace or supplement a urodynamic examination and also be used when urodynamics alone is not applicable, for example if the patient cannot urinate or uses a catheter. The product can also be used while waiting for an active treatment.

"This approval is important in our efforts to strengthen IP protection around our stand-alone products and their future uses. Urodynamics is usually a bottleneck in healthcare with long waiting times of several months. With our product, the doctor can get answers to some of their questions within 30 minutes", says CEO Johan Wennerholm in a comment.

For further information, please contact:

---

Johan Wennerholm,  CEO
Tel. [phone]
Email: [e-mail]

About ProstaLund

---

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: [phone]
E-mail: [e-mail]

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-15 12:00 CEST.

Attachments

---

Patent has been approved in China

© Modular Finance, source Nordic Press Releases